Nexalin's New Alzheimer's Data Shows Memory Gains in Half of Treated Patients
NXL is trading near its 52-week low of $5.938 (1.8% above the low) on elevated volume (3.2× avg).
Summary
Nexalin released a secondary analysis of its 46-patient Alzheimer's trial showing 10 of 20 active-arm participants achieved a clinically meaningful ≥4-point ADAS-Cog improvement, with gains in memory, comprehension, and language still evident three months after treatment. The largest improvements (8 points) occurred in patients with the greatest baseline impairment. These post-hoc findings are exploratory and not adjusted for multiple comparisons, but they directly inform endpoint and patient selection for the planned U.S. pilot study. This follows the company's Q-Submission meeting with the FDA and comes amid a going concern warning and Nasdaq delisting threat. The data could strengthen the case for the upcoming pilot study, but the company's financial constraints remain a key risk.
At the time of this announcement, NXL was trading at $6.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $5.94 to $60.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.